What novel therapies are being investigated for the treatment of human leukocyte antigen (HLA) B27–associated acute anterior uveitis (AAU)?

Updated: Apr 09, 2021
  • Author: Huy D Nguyen, MD, MBA; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print


Therapies for uveitis remain nonspecific in their mode of action, and they have a number of adverse effects leading to increased interest in immunomodulatory therapies such as antitumor necrosis factor alpha (anti-TNF-alpha) and the use of HLA-B27 oral tolerance therapy. TNF-alpha has been shown to be a critical inflammatory instigator in the pathogenesis of various forms of uveitis, including AAU, in both animal and human experimental studies. Anti-TNF-alpha infliximab is a murine-human chimeric monoclonal antibody directed against human TNF-alpha. It has been shown to be a rapid, effective, and safe therapy of vision-threatening ocular inflammation in Behcet disease and refractory posterior uveitis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!